White matter lesion load is associated with resting state functional MRI activity and amyloid PET but not FDG in mild cognitive impairment and early Alzheimer's Disease patients

Journal of Magnetic Resonance Imaging

Volumn 41, Issue 1, 2015, Pages 102-109

  Zhou, Yongxia ^a,b   Yu, Fang ^c,d   Duong, Timothy Q ^c,d  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

Alzheimer disease; Amyloid; Default mode network; Fractional amplitude at low frequency fluctuation; Resting statefMRI; White matter lesion

Indexed keywords

AMYLOID; FLORBETAPIR F 18; FLUORODEOXYGLUCOSE F 18; GLUCOSE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN CORTEX; CLINICAL ARTICLE; CONTROLLED STUDY; DEFAULT MODE NETWORK; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLUCOSE METABOLISM; HUMAN; IMAGE ANALYSIS; MALE; MILD COGNITIVE IMPAIRMENT; PARIETAL CORTEX; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PREFRONTAL CORTEX; QUANTITATIVE ANALYSIS; TEMPORAL CORTEX; WHITE MATTER LESION; AMYLOID PLAQUE; BRAIN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROCEDURES; REST; SCINTISCANNING; WHITE MATTER;

AGED; ALZHEIMER DISEASE; BRAIN; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MILD COGNITIVE IMPAIRMENT; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REST; WHITE MATTER;

EID: 84919402734     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.24550     Document Type: Article

References (40)

1. Chui HC. Vascular cognitive impairment: today and tomorrow. Alzheimers Dement 2006;2:185-194.
2. Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ 2010;341:c3666.
3. Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013;12:822-838.
4. Geppert AM, Wroblewska KA, Przedpelska-Ober EM. Greater frequency of subcortical lesions in severely demented patients with early onset Alzheimer's disease. Alzheimers Dement 2007;3:54-57.
5. Brickman AM, Provenzano FA, Muraskin J, et al. Regional white matter hyperintensity volume, not hippocampal atrophy, predicts incident Alzheimer disease in the community. Arch Neurol 2012; 69:1621-1627.
6. Ryan NS, Keihaninejad S, Shakespeare TJ, et al. Magnetic resonance imaging evidence for presymptomatic change in thalamus and caudate in familial Alzheimer's disease. Brain 2011;136: 1399-1414.
7. Salat DH, Tuch DS, Greve DN, et al. Age-related alterations in white matter microstructure measured by diffusion tensor imaging. Neurobiol Aging 2005;26:1215-1227.
8. Zhou Y, Dougherty JH Jr, Hubner KF, Bai B, Cannon RL, Hutson RK. Abnormal connectivity in the posterior cingulate and hippocampus in early Alzheimer's disease and mild cognitive impairment. Alzheimers Dement 2008;4:265-270.
9. Nordahl CW, Ranganath C, Yonelinas AP, DeCarli C, Fletcher E, Jagust WJ. White matter changes compromise prefrontal cortex function in healthy elderly individuals. J Cogn Neurosci 2006;18: 418-429.
10. Patel MJ, Boada FE, Price JC, et al. Association of small vessel ischemic white matter changes with BOLD fMRI imaging in the elderly. Psychiatry Res 2012;204:117-122.
11. Whitwell JL, Jack CR Jr, Duffy JR, et al. Microbleeds in the logopenic variant of primary progressive aphasia. Alzheimers Dement 2013;9:1-5.
12. Braak H, Braak E. Neuropathological stageing of Alzheimerrelated changes. Acta Neuropathol 1991;82:239-259.
13. Moghekar A, Kraut M, Elkins W, et al. Cerebral white matter disease is associated with Alzheimer pathology in a prospective cohort. Alzheimers Dement 2012;8(Suppl):S71-S77.
14. Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005;25:7709-7717.
15. Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 2001;286:2120-2127.
16. Takada LT, Camiz P, Grinberg LT, da Costa Leite C. Non-inflammatory cerebral amyloid angiopathy as a cause of rapidly progressive dementia - a case study. Dement Neuropsychol 2009;3: 352-257.
17. Zhou Y, Ge Y, De Leon M. White matter lesion load is associated with resting state fMRI activity in mild cognitive impairment patients. Alzheimers Dement 2012;8:535-536.
18. Reed BR, Marchant NL, Jagust WJ, Decarli C, Mack W, Chui HC. Coronary risk corrlates with cerebral amyloid deposition. Neurobiol Aging 2012;33:1979-1987.
19. Zhou Y, Lui YW, Zuo X-N, et al. Characterization of thalamocortical association using amplitude and connectivity of fMRI in mild traumatic brain injury. J Magn Reson Imaging 2013 (in press).
20. Zhou Y, Milham MP, Lui YW, et al. Default-mode network disruption in mild traumatic brain injury. Radiology 2012;265:882-892.
21. Greicius MD, Krasnow B, Reiss AL, Menon V. Functional connectivity in the resting brain: a network analysis of the default mode hypothesis. Proc Natl Acad Sci U S A 2004;101:4637-4642.
22. Mikheev A, Nevsky G, Govindan S, Grossman R, Rusinek H. Fully automatic segmentation of the brain from T1-weighted MRI using Bridge Burner algorithm. J Magn Reson Imaging 2008;27:1235-1241.
23. Damian MS, Schilling G, Bachmann G, Simon C, Stoppler S, Dorndorf W. White matter lesions and cognitive deficits: relevance of lesion pattern? Acta Neurol Scand 1994;90:430-436.
24. Bendfeldt K, Blumhagen JO, Egger H, et al. Spatiotemporal distribution pattern of white matter lesion volumes and their association with regional grey matter volume reductions in relapsingremitting multiple sclerosis. Hum Brain Mapp 2010;31:1542-1555.
25. Mortamais M, Reynes C, Brickman AM, et al. Spatial distribution of cerebral white matter lesions predicts progression to mild cognitive impairment and dementia. PloS One 2013;8:e56972.
26. Huang KL, Lin KJ, Hsiao IT, et al. Regional amyloid deposition in amnestic mild cognitive impairment and Alzheimer's disease evaluated by [(18)F]AV-45 positron emission tomography in Chinese population. PloS One 2013;8:e58974.
27. La Joie R, Perrotin A, Barre L, et al. Region-specific hierarchy between atrophy, hypometabolism, and b-amyloid (Ab) load in Alzheimer's disease dementia. J Neurosci 2012;32:16265-16273.
28. Nordberg A, Carter SF, Rinne J, et al. A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. Eur J Nucl Med Mol Imaging 2013;40:104-114.
29. Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013;12:207-216.
30. Mosconi L, Berti V, Glodzik L, Pupi A, De Santi S, de Leon MJ. Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging. J Alzheimers Dis 2010;20:843-854.
31. Rusinek H, Endo Y, De Santi S, et al. Atrophy rate in medial temporal lobe during progression of Alzheimer disease. Neurology 2004;63:2354-2359.
32. Sperling RA, Johnson KA, Doraiswamy PM, et al. Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiol Aging 2013;34:822-831.
33. Drzezga A, Becker JA, Van Dijk KRA, et al. Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden. Brain 2011;134:1635-1646.
34. Sheline YI, Raichle ME, Snyder AZ, et al. Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Bio Psychiatry 2010;67:584-587.
35. Doraiswamy PM, Sperling RA, Coleman RE, et al. Amyloid-beta assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology 2012;79:1636-1644.
36. Storandt M, Mintun MA, Head D, Morris JC. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol 2009; 66:1476-1481.
37. Stern Y. Cognitive reserve in ageing and Alzheimer's disease. Lancet Neurol 2012;11:1006-1012.
38. Kling MA, Trojanowski JQ, Wolk DA, Lee VM, Arnold SE. Vascular disease and dementias: paradigm shifts to drive research in new directions. Alzheimers Dement 2013;9:76-92.
39. Herrup K, Carrillo MC, Schenk D, et al. Beyond amyloid: getting real about nonamyloid targets in Alzheimer's disease. Alzheimers Dement 2013;9:452-458.
40. Kling MA, Trojanowski JQ, Wolk DA, Lee VM, Arnold SE. Vascular disease and dementias: paradigm shifts to drive research in new directions. Alzheimers Dement 2013;9:76-92.